The impact of genomics on anti-infectives drug discovery and development

scientific article

The impact of genomics on anti-infectives drug discovery and development is …
instance of (P31):
scholarly articleQ13442814
review articleQ7318358

External links are
P356DOI10.1016/S0966-842X(02)02427-7
P698PubMed publication ID12377564

P2093author name stringTanya Parkinson
P2860cites workGenome-wide expression patterns in Saccharomyces cerevisiae: comparison of drug treatments and genetic alterations affecting biosynthesis of ergosterolQ39473756
Helicobacter pylori strain-specific differences in genetic content, identified by microarray, influence host inflammatory responsesQ39907255
The role of a mutant CCR5 allele in HIV-1 transmission and disease progression.Q43521980
Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics studyQ43865209
Individual acid aspartic proteinases (Saps) 1-6 of Candida albicans are not essential for invasion and colonization of the gastrointestinal tract in miceQ43866993
Virogenomics: a novel approach to antiviral drug discoveryQ45877976
IVET and RIVET: use of gene fusions to identify bacterial virulence factors specifically induced in host tissues.Q50118831
Computer-aided target selection-prioritizing targets for antifungal drug discoveryQ77420483
Complete Genome Sequence of Neisseria meningitidis Serogroup B Strain MC58Q22065549
Structural genomics: A pipeline for providing structures for the biologistQ27638461
Substrate promiscuity of an aminoglycoside antibiotic resistance enzyme via target mimicryQ27638972
Functional discovery via a compendium of expression profilesQ27938962
Estimating the number of protein folds and families from complete genome dataQ30597194
Signature-tagged and directed mutagenesis identify PABA synthetase as essential for Aspergillus fumigatus pathogenicityQ30897609
In vivo genetic analysis of bacterial virulenceQ33765927
Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing.Q33892877
Ethical considerations in clinical pharmacogenomics researchQ33953253
Genomics-based identification of targets in pathogenic bacteria for potential therapeutic and diagnostic use.Q34179576
Ethical and legal implications of pharmacogenomicsQ34188160
Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatmentQ34188511
Antibacterial vaccine design using genomics and proteomicsQ34217850
The genomics and genetics of human infectious disease susceptibilityQ34433495
Privacy and confidentiality of genetic information: what rules for the new science?Q34433499
Use of signature-tagged mutagenesis in pathogenesis studiesQ34521789
The pharmacogenomics of HIV therapy.Q34574033
Comparing genomes within the species Mycobacterium tuberculosisQ35033207
Exploring drug-induced alterations in gene expression in Mycobacterium tuberculosis by microarray hybridizationQ36558993
Mycobacterium species identification and rifampin resistance testing with high-density DNA probe arrays.Q39445682
P433issue10 Suppl
P921main subjectgenomicsQ222046
drug discoveryQ1418791
P304page(s)S22-6
P577publication date2002-01-01
P1433published inTrends in MicrobiologyQ15265732
P1476titleThe impact of genomics on anti-infectives drug discovery and development
P478volume10

Reverse relations

cites work (P2860)
Q28602660Neglected tropical diseases in the genomics era: re-evaluating the impact of new drugs and mass drug administration
Q33195402Novel therapeutic targets in Helicobacter pylori
Q59290682Selection of a DNA barcode for Nectriaceae from fungal whole-genomes
Q46023519The evolving role of infectomics in drug discovery.
Q36156270Unraveling the secret lives of bacteria: use of in vivo expression technology and differential fluorescence induction promoter traps as tools for exploring niche-specific gene expression

Search more.